Data from Pharmawand - Curated by EPG Health - Date added 22 June 2019

Alexion Pharmaceuticals, Inc. announced that the FDA has accepted for priority review the company’s supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, for the treatment of people with atypical hemolytic uremic syndrome (aHUS) in order to inhibit complement-mediated thrombotic microangiopathy (TMA). The FDA has set a target action date of 19 October 2019 under the Prescription Drug User Fee Act (PDUFA).

The sBLA is based on previously announced results, which were recently presented at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress , from the Phase III study of Ultomiris in people with aHUS, which met the primary endpoint of complete TMA response, defined by hematologic normalization and improved kidney function.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Load more

Related Content